Companies are facing a challenging decision regarding the use of GLP-1 therapies, as new research from Aon highlights both immediate costs and potential long-term savings. Aon’s analysis of commercial health-claims data indicates that while GLP-1 drugs can lead to significant clinical benefits, particularly for women, they also pose substantial upfront pharmacy costs for employers.
In a comprehensive phase-two study, Aon examined de-identified medical and pharmacy claims for approximately 192,000 individuals who initiated GLP-1 therapy. The data, sourced from a dataset covering tens of millions of commercially insured lives, revealed that female users of these therapies experienced about a 50 percent reduction in ovarian cancer incidence and a 47 percent decrease in hospitalizations for major cardiovascular events. Aon emphasized that patients adhering to their medication—defined as at least 80 percent adherence—saw the most significant slowdown in medical-cost growth.
Despite these promising findings, the financial implications for employers are immediate and pressing. The rising utilization of GLP-1 therapies has led to increased pharmacy spending, creating substantial liabilities for benefits teams that must be addressed in the short term. Industry reports have shown that many members experience double-digit increases in both medical and pharmacy claims within the first year of therapy, complicating the return-on-investment calculations for employers.
Assessing the Financial Impact on Employers
Employers are now tasked with evaluating whether the initial financial burden of GLP-1 therapies is justified by the potential for reduced costs associated with hospitalizations and chronic diseases in the future. Farheen Dam, Aon’s North America health solutions leader, stated, “The real impact comes when employers consider not just coverage, but also how these medications are used, supported, and sustained over time.” Aon recommends that employers combine GLP-1 access with adherence support and comprehensive wellbeing programs to maximize clinical benefits and achieve long-term savings.
Despite this guidance, many employers are cautious about extending GLP-1 benefits. Recent surveys, including findings from KFF and a Mercer employer survey, reveal that coverage for GLP-1s, particularly for weight loss, varies significantly. Large employers often implement prior-authorization requirements and eligibility restrictions, resulting in a mixed approach to coverage. Some plan sponsors view GLP-1 therapies as a long-term investment, while others perceive them as a potential budgetary strain.
Future Implications for Workplace Health Benefits
The analysis by Aon has already attracted attention from business outlets, including Crain’s Chicago Business. As pricing trends, adherence data, and policy regulations continue to evolve, the findings are expected to play a significant role in upcoming discussions surrounding benefits planning. For human resources teams, the decision-making process hinges on several factors, including program design, manufacturer pricing, and the verification of clinical outcomes flagged by Aon through independent research.
Ultimately, how employers navigate the complexities of GLP-1 coverage could determine whether these therapies become a strategic advantage or a costly experiment. Balancing immediate financial pressures against the promise of long-term health improvements will be crucial as the healthcare landscape continues to change.
